Riddall, Dieter,Leach, Michael,Harbige, Laurence,Franzmann, Karl
申请号：
AU2009205396
公开号：
AU2009205396B2
申请日:
2009.01.16
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
Compounds of general structure in which X and Y are each N or C with at least one ofX and Y being N； Z is a single bond or an optionally substituted linking group R1is hydrogen or a substituent group； R2 is amino or a substituent group； N* is aminowhen RI is hydrogen or =NH when R1 is a substituent group； or N* is a group NRaRb whereRa and Rb are independently H or an alkyl group； or N* is an optionally substitutedpiperazinyl ring； and A is an optionally substituted heterocyclic or carbocyclicring system which may be linked to the triazo/diazo ring through R2 to form a fusedmulticyclic ring； are indicated as suitable for treatment of disorders in mammalsthat are susceptible to sodium channel blockers and antifolates, and particularlydisorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebraltraumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgicaltrauma, neurodegenerative disorders, motorneurone disease, Alzheimer'sdisease, Parkinson's disease, chronic inflammatory pain, neuropathicpain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophreniaand trigeminal autonomic cephalalgias； for treatment of mammalian cancers；and for treatment of malaria.
